Published in Cirugia y cirujanos
La sensibilidad foveal en el edema macular diabético con agudeza visual 20/20 es menor en ojos con edema macular clínicamente significativo sin engrosamiento del centro de la mácula y agudeza visual 20/20. Determinar el valor pronóstico de esta disfunción requiere una evaluación adicional para identificar si se necesita tratamiento temprano en esto...
Published in Endocrinologia, diabetes y nutricion
Vascular endothelial growth factor (VEGF) plays an essential role in development of diabetic macular edema (DME). While there is evidence suggesting that silymarin, a flavonoid extracted from Silybum marianum, could be useful for prevention and treatment of diabetic nephropathy, no studies have been conducted in diabetic retinopathy (DR). The aim o...
Published in Ophthalmologica
Objetivo: Comparar la efectividad de ranibizumab intravítreo (RIV) para el tratamiento del edema macular diabético (EMD) en ojos con y sin vitrectomía previa. Procedimientos: Evaluamos de manera prospectiva la mejor agudeza visual corregida (MAVC) y el grosor macular central (GMC) tras el tratamiento con RIV durante 6 meses. Resultados: No se obser...
Published in Archivos de la Sociedad Espanola de Oftalmologia
To compare subfoveal choroidal thickness (GCSF) in patients with diabetic macular oedema (DMO) and healthy subjects using swept source optical coherence tomography (SS-OCT). Cross-sectional study including 50 eyes of 36 patients with DMO, and 47 eyes of 34 patients as a control group. GCSF was measured in both groups, analysing between the eyes wit...
Published in Cirugia y cirujanos
Macular oedema is a form of diabetic retinopathy that can be treated with photocoagulation. The expected effect of treatment varies, and may depend on the previous characteristics of retinal thickening. To determine whether the change in retinal thickness after focal photocoagulation for diabetic macular oedema varies due to the presence of anatomi...
Published in Cirugia y cirujanos
There was no statistical difference in the proportion of eyes with visual improvement between patients treated with angiotensin converting enzyme inhibitors and in those where they were not used. There is no support for the inhibition of angiotensin II in addition to photocoagulation for improving the outcome in patients with diabetic macular oedem...
Published in Cirugia y cirujanos
Retinal thickening and visual acuity improved or did not change in 71.3% of eyes with diabetic macular oedema with a single photocoagulation procedure. Retinal variables that are usually evaluated were unable to identify the remaining 28.7%, which could lose vision after that treatment, and would require additional interventions.
Published in Cirugia y cirujanos
Retinal thickening and visual acuity improved or did not change in 71.3% of eyes with diabetic macular oedema with a single photocoagulation procedure. Retinal variables that are usually evaluated were unable to identify the remaining 28.7%, which could lose vision after that treatment, and would require additional interventions.
Published in Cirugia y cirujanos
There was no statistical difference in the proportion of eyes with visual improvement between patients treated with angiotensin converting enzyme inhibitors and in those where they were not used. There is no support for the inhibition of angiotensin II in addition to photocoagulation for improving the outcome in patients with diabetic macular oedem...
Published in Archivos de la Sociedad Espanola de Oftalmologia
Aflibercept is a new anti-vegf drug that, unlike ranibizumab and bevacizumab blocks both vegf-A and placental growth factor. Moreover, it binds with much greater strength and affinity to human VEGF-A165 than other endogenous vegf receptors, conferring it with a more extended effect and allowing a lower frequency of intravitreal injections. This fac...
